Highlights

  • Acrux shares remained flat at AUD 0.011 on 14 May 2026 after touching an intraday high of AUD 0.012.
  • Acrux confirmed its Pooled Development Fund structure continues to provide Capital Gains Tax exemptions for shareholders.
  • The company recently secured AUD 1.6 million through a share Placement backed by institutional and professional investors.
  • Placement Demand exceeded the raising target, with commitments totalling AUD 2.6 million.
  • Funds raised are intended to support development of Acrux’s female testosterone program and co-development discussions with an international partner

Acrux Ltd (ASX:ACR) traded flat at AUD 0.011 during the session on 14 May 2026, although the stock briefly climbed to an intraday high of AUD 0.012 before easing back as selling pressure persisted. While the company released a fresh market update linked to capital gains tax treatment for shareholders, the broader share price trend remains subdued, with Acrux shares still down 63.3% over the past 12 months.

The latest announcement from the specialty pharmaceutical company focused on the implications of recent Federal Budget changes to Australia’s capital gains tax framework. Acrux informed the market that shareholders remain exempt from capital gains tax on profits derived from the sale of Acrux shares due to the company’s status as a registered Pooled Development Fund (PDF).

The update arrived only days after Acrux announced a AUD 1.6 million capital raising aimed at supporting development activities surrounding its female testosterone program and advancing discussions with an international commercial partner.

Acrux operates as an Australian drug delivery and specialty pharmaceutical company focused on developing and commercialising topical healthcare products. Over more than two decades, the company has built experience in transdermal and topical pharmaceutical technologies, with several products commercialised globally through licensing arrangements. The company’s strategy remains centred on developing patient-focused healthcare products supported by proprietary technologies and intellectual property protections.

Federal Budget Changes Bring Focus to Acrux’s PDF Structure

In its 14 May 2026 ASX release, Acrux highlighted that the Australian Federal Government’s 2026/27 Budget included major changes to the application of capital gains tax in Australia. Under the announced reforms, the current 50% capital gains tax discount is scheduled to be replaced from 1 July 2027 with a system involving cost base indexation and a minimum 30% tax on net capital gains.

However, Acrux clarified that these changes do not alter the taxation treatment applicable to shareholders due to the company’s status as a registered Pooled Development Fund.

According to the company, capital gains and losses associated with the sale of shares in registered PDFs remain exempt from taxation. Acrux also noted that dividends paid by the company continue to remain exempt from income tax under the PDF framework.

The company used the announcement to reiterate the original purpose behind the Pooled Development Fund Act 1992, which was introduced by the Australian Government to increase Investment capital flowing into small and medium-sized enterprises. The legislation established concessional tax treatment for eligible investments as a way of encouraging investor participation in growth-focused businesses.

Acrux additionally advised shareholders that the announcement represented general information only and encouraged investors to seek independent taxation advice relevant to their individual circumstances.

Investors Monitor Recent Capital Raising Activity

While the 14 May update primarily addressed taxation matters, market attention has also remained on Acrux’s recent capital raising announced earlier in the week.

On 11 May 2026, the company confirmed it had secured binding commitments from institutional and professional investors to raise AUD 1.6 million before costs through a share placement.

The placement was conducted at an issue price of 0.95 cents per share. Acrux disclosed that investor demand exceeded the intended raising amount, with bids totalling approximately AUD 2.6 million. As a result, the placement was scaled back by AUD 1.0 million.

The level of investor participation appeared notable given the company’s recent share price weakness and broader Volatility across smaller healthcare and biotechnology stocks.

Under the structure of the raising, participating investors are also expected to receive one unlisted attaching option for every two shares subscribed for, subject to Shareholder approval. These Options are proposed to carry an exercise price of AUD 0.018 and a three-year expiry period.

The attaching options are expected to be presented for shareholder approval at an Extraordinary General Meeting anticipated to take place in July 2026.

Funds Target Female Testosterone Development Program

Acrux stated that proceeds from the placement are intended to support continued development of its female testosterone product candidate while also assisting the company in progressing toward a co-development agreement with an international partner.

The company has increasingly positioned the female testosterone opportunity as a key focus area within its development pipeline.

Chief Executive Officer and Managing Director John Warmbrunn said the placement received favourable support from both existing and new shareholders. He also indicated that excess demand for the raising reflected investor interest in the company’s Phase III clinical trial activities and the proposed co-development pathway.

Management additionally pointed to growing global demand associated with hypoactive sexual desire dysfunction (HSDD), a condition affecting women that the company believes remains under-addressed in international healthcare markets.

Acrux noted that its existing experience in commercialised pharmaceutical products and topical drug delivery technologies provides a platform to support development efforts in this segment.

Discounted Placement Reflects Funding Conditions

The placement was completed at a discount to Acrux’s recent trading levels, reflecting typical financing conditions for emerging healthcare companies seeking development capital.

The issue price represented a 13.6% discount to the company’s last traded share price of AUD 0.011 and a 16.8% discount to the five-day Volume weighted average price of AUD 0.0114 leading into 9 May 2026.

Lead manager fees associated with the raising included options to be issued on similar terms to placement participant options, excluding shares introduced directly by Acrux.

The company did not disclose any changes to operational guidance alongside the placement announcement, with the primary emphasis remaining on funding support for pipeline development and Partnership activities.

Acrux Continues Building on Drug Delivery Expertise

Beyond the immediate announcements, Acrux continues to position itself as a specialist in topical and transdermal pharmaceutical product development.

The company has operated in the healthcare sector for approximately 25 years and has commercialised several products through international licensing partnerships, particularly in the United States market.

Its development model focuses on combining formulation expertise with patient-preferred delivery systems, while also leveraging Patent protections and proprietary technologies where possible.

Acrux has stated that its internal expertise and established product development experience form part of its broader strategy to create value through both internally developed and acquired healthcare technologies.

While investor focus currently appears centred on funding requirements and clinical development milestones, future market attention may also remain tied to any updates surrounding international partnership discussions connected to the female testosterone program.

Share Price Performance Remains Weak Over One Year

Despite the recent announcements, Acrux shares continue to trade significantly below levels seen a year ago. The stock has declined 63.3% over the past 12 months, reflecting ongoing pressure across segments of the small-cap healthcare and biotechnology sector.

Although the stock briefly moved higher intraday on 14 May 2026, gains were not sustained through the session.

The muted share price response suggests investors may remain cautious while monitoring future funding requirements, development timelines, regulatory pathways and potential commercial partnership outcomes.

At the same time, the oversubscribed placement and continued investor interest in the company’s clinical development strategy indicate that parts of the market continue to follow Acrux’s pipeline progress closely.

What This Means for Investors?

Acrux’s latest market update clarified that shareholders continue to retain capital gains tax exemptions under the company’s Pooled Development Fund structure despite upcoming Federal Budget changes to CGT rules.

Alongside this, the company recently secured AUD 1.6 million in fresh funding to support its female testosterone development program and ongoing co-development discussions with an international partner.

While the share price remains under pressure on a longer-term basis, recent developments suggest investor attention remains focused on future clinical milestones, funding progress and potential partnership outcomes tied to Acrux’s pharmaceutical pipeline.